Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic Investigation of the Neuroprotective and Anti-Inflammatory Effects of Undaria pinnatifida Fucoidan In Vivo

ABSTRACT: Undaria pinnatifida fucoidan (UPF), a bioactive sulphated polysaccharide, has been widely recognised for its anti-inflammatory, antioxidant, antitumor, anticoagulant, antiviral, and immunomodulatory properties. However, the precise mechanisms through which UPF regulates systemic inflammation, oxidative stress, and neuronal health remain unclear. This study aimed to investigate the effects of UPF supplementation on systemic inflammation, gut microbiota composition, and neuronal protein expression in a murine model. A total of 64 C57BL/6J mice were administered UPF (400 mg/kg/day) for 10 weeks, and its impact on key inflammatory markers, gut microbiota, and neuronal proteins was assessed. UPF significantly downregulated pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in skeletal muscle, small intestine, and hypothalamus, while also reducing circulating IL-1α levels. Moreover, UPF altered gut microbiota composition by decreasing the abundance of the inflammatory bacterial marker Enterobacteriales order. In the brain, proteomic analysis of the nucleus accumbens revealed that UPF modulated the expression of proteins involved in immune response, neuronal stability, oxidative and endoplasmic reticulum stress, neurotransmitter regulation, and neuroinflammation. These findings suggest that UPF supplementation effectively mitigates systemic inflammation, supports muscle and gut health, and enhances neuronal function, highlighting its potential as a therapeutic intervention for inflammation-related disorders and neurodegenerative diseases.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Richard Wilson

LAB HEAD: Dr Richard Wilson

PROVIDER: PXD060861 | Pride | 2026-06-29

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	2311_CY_01.raw	Raw
	2311_CY_02.raw	Raw
	2311_CY_03.raw	Raw
	2311_CY_04.raw	Raw
	2311_CY_05.raw	Raw

Items per page:

1 - 5 of 44

Similar Datasets

HPA-Gut Microbiome Axis Dysregulation in Sleep Deprivation: Pharmacological and Microbial Rescue of Lacrimal Gland Homeostasis

Project description:Sleep deprivation (SD) disrupts systemic homeostasis, yet its impact on lacrimal gland integrity through neuroendocrine–microbial pathways remains unclear. Using a male mice SD model, we show that chronic SD activates the hypothalamic-pituitary-adrenal (HPA) axis, elevates corticosterone, alters gut microbiota, and depletes short-chain fatty acids (SCFAs). These alterations coincide with lacrimal gland atrophy, reduced tear secretion, and increased CD4⁺/CD8⁺ T cell infiltration, accompanied by activation of IL-17-associated inflammatory pathways. Pharmacological inhibition of glucocorticoid synthesis with metyrapone preserves lacrimal gland structure and function while attenuating immune activation. Microbiome-directed interventions, including SCFA supplementation and fecal microbiota transplantation, rebalance gut communities, suppress proinflammatory T cell responses, and maintain lacrimal gland homeostasis. Transcriptomic and immunohistochemical analyses further reveal that all three interventions converge on downregulation of IL-17 signaling. Collectively, these findings establish an HPA-gut microbiome-lacrimal gland axis links neuroendocrine stress to microbial dysbiosis and ocular inflammation, and they suggest therapeutic strategies for SD-associated lacrimal gland dysfunction.

2025-12-21 | GSE302528 | GEO

Supplementation with Probiotic Lactobacillus plantarum 299v in Men With Stable Coronary Artery Disease Suppresses Systemic Inflammation

Project description:Recent clinical trials demonstrate the efficacy of treatment strategies to reduce cardiovascular events in patients with coronary artery disease (CAD) that focus in reducing inflammatory signaling. Emerging data implicate the gut microbiota as a critical regulator of systemic inflammation. We recently demonstrated that supplementation with Lactobacillus plantarum 299v (Lp299v) improved vascular endothelial function in men with stable CAD. In this study we investigated whether the favorable effects of Lp299v on vascular health are due in part to coordinated suppression of systemic inflammation. We applied pre- and post-Lp299v supplementation plasma from these patients to peripheral blood mononuclear cells of a healthy donor to determine the transcriptional response to this intervention.

2021-02-24 | GSE156357 | GEO

Probiotic normalization of systemic inflammation in siblings of Type 1 diabetes patients

Project description:BACKGROUND. The incidence of Type 1 Diabetes (T1D) has significantly increased in recent decades and coincides with lifestyle changes that have likely altered the composition of the gut microbiota. Dysbiosis and gut barrier dysfunction are associated with T1D, and notably, our studies have identified an inflammatory state in T1D families that is consistent microbial antigen exposure. METHODS. We conducted a 6-week, single-arm, open-label trial to investigate whether daily multi-strain probiotic (Bifidobacteria, Lactobacillus, and Streptococcus) supplementation could reduce the familial inflammatory state in 25 unaffected siblings of diabetes patients. RESULTS. Probiotic supplementation was found safe and well-tolerated; there were no adverse events and participant adherence was 93%. Bacterial 16S rDNA gene sequencing of stool revealed that community alpha and beta diversity were not altered between the pre- and post-supplement samplings. LEfSe analyses identified post-supplement enrichment of the family Lachnospiraceae, producers of the anti-inflammatory short chain fatty acid butyrate. Systemic inflammation was measured by plasma induced transcription and quantified with a gene ontology-based composite inflammatory index (I.I.com). After supplementation, I.I.com was reduced (p=0.017), and pathway analysis predicted inhibition of IL17A, lipopolysaccharide, NFkB, IL1B, and TNF (Z-score≤-2.0) and activation of IL10RA (Z-score=2.0). Post-supplement plasma levels of IL12p40, IL-13, IL-15, IL-18, CCL2, CCL24 were reduced (p<0.05), while butyrate levels trended 2.4-fold higher (p=0.06). CONCLUSION. There is a substantial need for safe, broadly applicable therapies to reduce T1D susceptibility. This study indicates that investigations of prebiotic and probiotic strategies are warranted as they may be efficacious either alone or in combination with other therapeutic agents.

2022-03-01 | GSE162622 | GEO

The effect of creatine supplementation on AOM/DSS induced colitis associated colorectal cancer in C57BL/6 mice

Project description:Colitis-associated colorectal cancer (CAC) is a serious complication of inflammatory bowel disease (IBD) with complex etiology involving chronic inflammation, immune dysregulation, and gut microbiota dysbiosis. Creatine, a natural nitrogenous com-pound, possesses anti-inflammatory and immunomodulatory properties, but its role in CAC remains unclear.We established an AOM/DSS-induced mouse model of CAC and supplemented mice with creatine. We assessed the effects of creatine on colitis severity, tumor burden, and histopathology. Additionally, we investigated the impact of crea-tine on gut barrier function, macrophage polarization, and gut microbiota composi-tion.Creatine supplementation significantly alleviated DSS-induced colitis, reduced tumor burden, and delayed CAC progression in mice. Mechanistically, creatine im-proved gut barrier function by protecting tight junction proteins from degradation in-duced by the modeling stimulus，influenced macrophage polarization, and main-tained gut microbiota diversity, promoting the abundance of beneficial bacteria while reducing harmful ones.Our findings suggest that creatine supplementation may rep-resent a promising supportive therapy for IBD and CAC by modulating the gut micro-biota and immune microenvironment. Further investigation is warranted to explore the clinical potential of creatine in the management of CAC.

2025-03-27 | GSE293077 | GEO

Expression data from oxaliplatin-treated tumors from mice pre-treated or not with antibiotics cocktail

Project description:The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. Here we show that disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy. In antibiotic-treated or germ-free mice, tumor-infiltrating myeloid-derived cells responded poorly to therapy, resulting in lower cytokine production and tumor necrosis after CpG-oligonucleotide treatment, and deficient production of reactive oxygen species and cytotoxicity following chemotherapy. Thus, optimal responses to cancer therapy require an intact commensal microbiota that mediates its effects by modulating myeloid-derived cell functions in the tumor microenvironment. These findings underscore the importance of the microbiota in the outcome of disease treatment. Oxaliplatin treatment induces expression of pro-inflammatory genes, which are inhibited by antibiotic pretreatment. Our goal was to ascertain the effect of antibiotic on the tumor gene expression profile prior to treatment and early on after the treatment with chemotherapy (oxaliplatin). The time points were selected t

2013-12-03 | E-GEOD-51414 | biostudies-arrayexpress

IL-17RC signaling connects intestinal microbiota and neuroimmune interactions in atherosclerosis

Project description:While dysbiosis and inflammation were previously implicated in cardiovascular diseases, the circuits of how microbiota drives distant perivascular innervation, neuroinflammation, and atherosclerosis remains unknown. Here, we report that IL-17RC signaling in the intestine protects from atherosclerosis controlling intestinal barrier and microbiota, and loss of IL-17RC in intestinal epithelial cells alters microbiota, enhances perivascular innervation and aortic inflammation, augmenting the disease. Neuronal outgrowth is functionally dependent on microbiota and is essential for neuroinflammation and augmentation of atherosclerosis as chemical denervation or chemogenetic inhibition reduces inflammation, macrophage activation and disease progression. Microbiota-dependent IL-17A producing gd T cells accumulate in the aorta to promote neuronal outgrowth and activation that can be reversed by gd T cell blockade. Perivascular neuron activation is further dependent on cell-autonomous IL-17 signaling as IL-17RC ablation in sympathetic neurons protected mice from microbiota-driven atherosclerosis. Together, our data illuminate how intestinal cytokine signaling distantly restrains neuroimmune interactions in aorta and uncovers a novel link between IL-17 signaling, microbiota, perivascular innervation and neuroimmune pro-inflammatory crosstalk instrumental for atherosclerosis progression.

2026-03-11 | GSE322757 | GEO

Aged gut microbiota contributes to systemical inflammaging after transfer to germ-free mice

Project description:Advanced age is associated with chronic low-grade inflammation, which is usually referred to as inflammaging. Elderly are also known to have an altered gut microbiota composition. However, whether inflammaging is a cause or consequence of an altered gut microbiota composition is not clear. In this study gut microbiota from young or old conventional mice was transferred to young germ-free mice. Four weeks after gut microbiota transfer immune cell populations in spleen, Peyer’s patches, and mesenteric lymph nodes from conventionalized germ-free mice were analyzed by flow cytometry. In addition, whole-genome gene expression in the ileum was analyzed by microarray. Gut microbiota composition of donor and recipient mice was analyzed with 16S rDNA sequencing. Here we show by transferring aged microbiota to young germ-free mice that certain bacterial species within the aged microbiota promote inflammaging. This effect was associated with lower levels of Akkermansia and higher levels of TM7 bacteria and Proteobacteria in the aged microbiota after transfer. The aged microbiota promoted inflammation in the small intestine in the germ-free mice and enhanced leakage of inflammatory bacterial components into the circulation was observed. Moreover, the aged microbiota promoted increased T cell activation in the systemic compartment. In conclusion, these data indicate that the gut microbiota from old mice contributes to inflammaging after transfer to young germ-free mice.

2018-02-14 | GSE104063 | GEO

Intestinal inflammation promotes gut commensal-specific CD4 T cell to initiate molecular mimicry-mediated neuroinflammation

Project description:The microbiota has been recognized as a critical contributor to various diseases, with multiple reports of changes in the composition of the gut microbiome in the context of not only inflammatory bowel disease (IBD), but also neurodegenerative diseases. These microbial shifts can exert systemic effects by altering the release of specific metabolites into the bloodstream, and the gastrointestinal microbiota has further been reported to exhibit immunomodulatory activity through the activation of innate and adaptive immunity. However, it remains unclear how the intestinal microbiota contributes to inflammation in the central nervous system (CNS), where these microorganisms are typically absent. Here, we report that ileum- and cecum-colonizing segmented filamentous bacteria (SFB)-specific T cells can induce inflammation in both the intestines and the CNS. Commensal-specific CD4 T cells that are dysregulated in the inflamed gut can become licensed to infiltrate into the CNS irrespective of their antigen specificity and have the potential to be re-stimulated by host protein-derived antigens in the CNS via molecular mimicry, whereupon they produce high levels of GM-CSF, TNFa, IFNg, and IL-17A, triggering neurological damage. We find that these infiltrated commensal-specific CD4 T cells initiate CNS inflammation by activating microglia through their IL-23R dependent encephalitogenic program and their IL-23R-independent GM-CSF production. Together, our findings reveal a potential mechanism whereby perturbation of commensal-specific T cells can contribute to extraintestinal inflammation.

2025-05-07 | GSE295643 | GEO

Intestinal inflammation promotes gut commensal-specific CD4 T cell to initiate molecular mimicry-mediated neuroinflammation

2025-05-07 | GSE295689 | GEO

Multi-omics reveal gut microbiota–metabolite–adipose axis as the driver of hesperidin-mediated metabolic improvement in obese mice

Project description:Hesperidin, a citrus flavonoid glycoside, was investigated for its protective effects against high-fat diet (HFD)-induced metabolic syndrome in mice. Twelve weeks of supplementation markedly attenuated body weight gain, hepatic steatosis, adipocyte hypertrophy, dyslipidemia, and systemic inflammation, while enhancing glucose tolerance and insulin sensitivity. 16S rRNA sequencing demonstrated that hesperidin partially restored microbial diversity and selectively enriched beneficial taxa, including Lactobacillus, Bifidobacterium, and Akkermansia. Serum metabolomics revealed increased levels of microbial-derived metabolites such as cinnamic acid, hippuric acid, and sulfated phenolic acids, compounds associated with anti-obesity, antioxidant and anti-inflammatory activities. Transcriptomic profiling of inguinal white adipose tissue identified broad remodeling of metabolic pathways, with notable activation of calcium signaling, implicating both UCP1-dependent browning and UCP1-independent calcium futile cycling in thermogenesis. Importantly, antibiotic treatment abolished the metabolic benefits and suppressed the generation of bioactive metabolites, underscoring the indispensable role of gut microbiota in hesperidin bioactivity. Together, these findings delineate a microbiota–metabolite–adipose tissue axis through which hesperidin confers systemic metabolic protection, highlighting its potential as a microbiota-targeted dietary strategy for managing obesity-related disorders.

2025-10-16 | GSE307989 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data